Hybridomas producing antibodies specific for lyme disease antigens OspA and OspB

US5856447A · kind A · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Markus Simon · Buckenhof, DE
• Ulrich E. Schaible · Freiberg, DE
• Klaus Eichmann · Glückstadt, DE
• Michael Kramer · Freiberg, DE
• Wallich Reinhard · Heidelberg, DE

Key dates

• Filing date: Feb 23, 1998
• Grant date: Jan 5, 1999
• Expiry date: Feb 23, 2018

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies, hybridomas and antigens.